Development of a Novel In Vitro Immuno-Competent Model of Dry Eye Disease and Its Use to Evaluate the Efficacy of an Ocular Surface Modulator

Ocul Immunol Inflamm. 2022 Oct-Nov;30(7-8):1816-1824. doi: 10.1080/09273948.2021.1961811. Epub 2021 Aug 11.

Abstract

Purpose: To develop an in vitro model of severe immunocompetent-dry eye disease (ic-DED) and to investigate the mechanism of action of a T-lysial ocular surface modulator.

Materials and methods: The reconstructed human corneal epithelium (HCE) was exposed to dryness stimuli. THP-1 cell infiltration into HCE was monitored at 4 h and 24 h from T-lysial application by immunohistochemistry (CD14, CD86, AQP3) and molecular biology (AQP3, TLR4 and TNF-α).

Results: A reduction of CD14, CD86 and AQP3 was observed after T-lysial treatment at 24 h. TLR4 was overexpressed in ic-DED model and downregulated by T-Lysial after 24 h. TNF-α expression was not modified.

Conclusion: The ic-DED model can be used to monitor the migration and differentiation of THP-1 into HCE. T-lysial was found to exert anti-inflammatory activity. This experimental model is a promising tool to study the crosstalk between epithelial and immune cells, providing new insights on the mechanisms of DED onset.

Keywords: Corneal epithelium; dry eye disease; immune cells; inflammation; ocular surface modulator.

MeSH terms

  • Dry Eye Syndromes* / drug therapy
  • Humans
  • Molecular Biology
  • Tumor Necrosis Factor-alpha*

Substances

  • Tumor Necrosis Factor-alpha